16.4 Clinical Protocols & Algorithms: Dietitian-Managed MBD, Anemia, Potassium & Nutrition-Support Pathways
Key Takeaways
Dietitian-managed protocols in dialysis units are physician-approved policies adopted under the medical director and state scope-of-practice rules; they do not create independent prescribing authority.
A sound protocol states the evidence base, inclusion and exclusion criteria, lab-based decision points, dose steps, monitoring intervals, escalation rules and documentation.
In a mineral-bone protocol, hypercalcemia calls for reducing calcium-based binders and active vitamin D before adding more calcium, and binder doses are tied to meals and snacks.
An iron protocol consistent with KDIGO 2026 starts IV iron in HD at ferritin 500 ng/mL or less and TSAT 30% or less, and holds routine iron above ferritin 700 ng/mL or TSAT 40%.
A nutrition-support pathway consistent with KDOQI 2020 moves from counseling to at least a 3-month oral supplement trial, then enteral feeding or a trial of IDPN if needs still are not met.
Why protocols are tested
Two CSR task statements apply: facilitate the use of protocols/algorithms used in medication management and utilize evidence-based protocols and guidelines (i.e., KDOQI) to deliver standardized care. In most U.S. dialysis units, much day-to-day adjustment of phosphate binders, active vitamin D, calcimimetics, iron and ESAs happens through approved protocols, and dietitians often run the mineral-bone and nutrition-support pathways. The exam expects you to apply a protocol correctly, spot a step that conflicts with current guidance, and know the limits of the dietitian's authority.
Authority and governance
- Physician approval. Protocols are orders adopted by the facility, usually approved by the medical director and the patient's nephrologist, who remain responsible for medical care. The dietitian acts under the protocol, within state licensure and scope-of-practice law and facility policy.
- No independent prescribing. Following a protocol is not independent prescribing. Changes outside the protocol, or any unclear case, go to the physician.
- Plan-of-care link. Changes made under a protocol must appear in the plan of care, which must use "current evidence-based professionally-accepted clinical practice standards" (42 CFR 494.90).
- Quality link. Protocol outcomes (for example, the share of patients with phosphorus in range) are QAPI indicators (§494.110). Protocols should be reviewed when guidelines change, for example after the KDIGO 2026 anemia update.
Anatomy of a well-built protocol
- Purpose and evidence base. For example: "Phosphorus management per KDOQI 2020 statements 6.3.1–6.3.2 and KDIGO 2017 CKD-MBD."
- Population: who is included (in-center HD adults) and excluded (pregnancy, hospitalized patients, transplant candidates within days of surgery).
- Monitoring schedule: for example, calcium and phosphorus monthly and intact PTH every 3 months.
- Decision points with explicit lab ranges and trends, not single values alone.
- Stepwise actions with dose increments and maximums.
- Hold and escalation rules: when to stop and call the physician (for example, calcium at or above 10.5 mg/dL, potassium at or above 6.0 mEq/L, or symptoms).
- Education and adherence checks before any dose increase: binder timing, supply and cost.
- Documentation and communication requirements.
- Competency requirements for staff who use the protocol.
Example 1: Mineral-bone disorder pathway (illustrative)
Phosphorus above the target range:
- Confirm the value and look for non-diet causes: missed treatments, inadequate Kt/V, very high PTH.
- Review intake: phosphate additives, portion sizes, and binders with every meal and snack.
- If adherence and diet are adequate, increase the binder by one step with meals, respecting limits on calcium-based binders.
- Recheck the next month.
Calcium above the upper limit (for example, uncorrected above 10.2 mg/dL):
- Reduce or stop calcium-based binders and switch to a non-calcium binder as the protocol allows.
- Reduce active vitamin D; notify the physician about calcimimetic options.
- Never answer high phosphorus by adding more calcium when calcium is already high.
Intact PTH trends:
- Rising toward or above about 9 times the upper limit of normal: consider active vitamin D or a calcimimetic per the physician's order, after correcting phosphorus and 25(OH)D.
- Falling below about 2 times the upper limit of normal: reduce vitamin D and calcimimetics to avoid adynamic bone disease.
- Hold calcimimetics if corrected calcium falls below the lower limit of normal.
Example 2: Iron and ESA pathway in hemodialysis (consistent with KDIGO 2026)
| Finding | Protocol action |
|---|---|
| Hb below target; ferritin 500 ng/mL or less and TSAT 30% or less; no active infection | IV iron course per the facility regimen, then proactive maintenance |
| Ferritin above 700 ng/mL or TSAT 40% or higher | Hold routine iron; look for inflammation or infection |
| Active bacteremia or infection | Hold IV iron; notify the physician |
| Hb at or below about 9–10 g/dL after correctable causes are fixed | Start or increase the ESA per protocol |
| Hb nearing 11.5 g/dL | Reduce the ESA dose; KDIGO recommends aiming below 11.5 g/dL, and FDA labeling advises reducing or interrupting near 11 g/dL |
| Dose adjustment timing | Change the ESA dose no more often than every 4 weeks, unless Hb rises more than 1 g/dL in 2–4 weeks, in which case reduce it |
| Poor ESA response | Work through iron, inflammation, blood loss, inadequate dialysis, hyperparathyroidism, B12 and folate |
Iron indices are tested every 1–3 months in HD, and more often after dose changes, blood loss or hospitalization.
Example 3: Pre-dialysis hyperkalemia pathway
- Potassium 5.6–5.9 mEq/L: review the diet (salt substitutes, juices, large portions, missed leaching), constipation, acidosis, drug causes, missed or shortened treatments and access recirculation. Counsel and recheck.
- Persistent elevation: ask the physician to review the dialysate potassium bath and consider a potassium binder (patiromer or SZC, with correct spacing from other drugs).
- Potassium at 6.0 mEq/L or higher, or symptoms or ECG changes: use the immediate physician notification and emergency pathway. Do not wait for the next monthly review.
Example 4: Nutrition-support pathway (consistent with KDOQI 2020)
- Screen at least biannually. Do a comprehensive assessment when screening flags risk: 7-point SGA, intake, weight trend, nPCR and albumin in context.
- Diagnose PEW or inadequate intake with a PES statement, and address causes: under-dialysis, depression, dentition, food access, acidosis.
- Counsel and fortify (small frequent meals, protein-dense foods, eating during dialysis where the facility allows it).
- Oral nutritional supplements: a trial of at least 3 months if counseling alone fails (2D).
- Enteral feeding trial if oral intake remains inadequate (OPINION).
- IDPN trial for maintenance HD patients whose needs cannot be met orally or enterally (2C). For PD, amino acid dialysate is not a general strategy but may be trialed when other routes fail.
- Reassess monthly while unstable, with defined stop criteria and goals.
Implementing and auditing protocols
- Gap analysis: compare current practice with guidelines, such as outdated iron ceilings or blanket 2 g potassium limits.
- Engage stakeholders (medical director, nurses, pharmacists, dietitians), train staff and pilot the protocol with a PDSA cycle.
- Audit and feedback: track the share of patients in range, protocol adherence and safety events (hypercalcemia, hypoglycemia, iron overload) through QAPI.
- Update when evidence changes, and document the review date and approval.
Common exam traps
- Increasing a calcium-based binder in a patient who is already hypercalcemic.
- Continuing IV iron at ferritin 900 ng/mL "because TSAT is low."
- A protocol step that tells the dietitian to diagnose or prescribe outside the approved order.
- Jumping straight to IDPN without an adequate oral supplement trial.
Under a facility's mineral-bone protocol, a hemodialysis patient has phosphorus 6.8 mg/dL, uncorrected calcium 10.6 mg/dL and intact PTH at 3 times the upper limit of normal. The patient takes calcium acetate with meals and oral calcitriol. Which protocol step is most appropriate?
Double the calcium acetate dose to lower phosphorus quickly.
Stop all binders until calcium normalizes.
Add calcium carbonate between meals to suppress PTH.
Reduce or stop the calcium-based binder in favor of a non-calcium binder, reduce the active vitamin D per protocol, reinforce binder timing and additive avoidance, and notify the physician about the hypercalcemia.
A dietitian reviews an old anemia protocol that says: 'Give maintenance IV iron unless ferritin exceeds 1,200 ng/mL.' Which revision brings it in line with KDIGO's 2026 guidance?
Hold routine iron when ferritin is above 700 ng/mL or TSAT is 40% or higher, and start iron in HD when ferritin is 500 ng/mL or less with TSAT 30% or less.
Raise the ceiling to 1,500 ng/mL because hemodialysis patients lose blood continuously.
Replace IV iron with oral iron for all hemodialysis patients.
Give iron only when hemoglobin falls below 8 g/dL.
Which statement best describes a dietitian's authority under a dialysis facility's physician-approved binder titration protocol?
The dietitian may prescribe any phosphate-lowering drug without physician involvement.
The dietitian adjusts binders only as the approved protocol specifies, within state scope-of-practice law and facility policy, documents the changes in the plan of care, and refers situations outside the protocol to the physician.
The protocol must be re-signed by the patient before every dose change.
Protocols are advisory only, so the dietitian may skip steps that seem unnecessary.
Sections you finish are checked off in the contents.
You've completed this section
Continue exploring other exams